NCT00588588

Brief Summary

The reported incidence of ventilator associated pneumonia (VAP) is 10 to 15 per 1,000 ventilator days. VAP leads to an excess cost exceeding $40,000 per patient and is associated with a crude mortality rate as high as 76%. The clinical criteria for the diagnosis of VAP have low specificity and may lead to unnecessary antibiotic use. The Clinical Pulmonary Infection Score (CPIS) and bronchoscopic approaches lower unnecessary antimicrobial use, antimicrobial resistance, and superinfection compared to the traditional clinical criteria. Based on the available evidence and local microbiology data, we have developed a VAP management protocol guided by CPIS or bronchoalveolar lavage (BAL) in adults with suspected VAP. These two approaches have not been compared against each other. Although the diagnostic studies in the CPIS guided approach are inexpensive and easily available, BAL has the potential to minimize the unnecessary use of antibiotics and reduce the development of drug resistant pathogens. In this study, we propose to test the hypothesis that BAL leads to a reduction in antibiotic use compared to CPIS in patients with suspected VAP. The study design will be a randomized, clinical trial comparing CPIS versus BAL. The primary outcome measure will be antibiotic utilization. The secondary outcome measures will be mortality, morbidity, development of resistant pathogens and superinfection and infection related financial burden. Completion of this trial will help us identify the best approach to avoid unnecessary antibiotic utilization and minimize the development of resistant pathogens (with their associated morbidity and mortality) in critically ill patients.

Trial Health

15
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Jan 2007

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2007

Completed
12 months until next milestone

First Submitted

Initial submission to the registry

December 22, 2007

Completed
17 days until next milestone

First Posted

Study publicly available on registry

January 8, 2008

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2009

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2009

Completed
Last Updated

September 26, 2023

Status Verified

September 1, 2023

Enrollment Period

2.3 years

First QC Date

December 22, 2007

Last Update Submit

September 25, 2023

Conditions

Keywords

Ventilator associated pneumoniaIntensive CareAntibioticsMortalityLength of stay

Outcome Measures

Primary Outcomes (1)

  • 14-day antibiotic free days

    Day 14 of enrolment

Secondary Outcomes (3)

  • Mortality

    28 days

  • Daily organ failure score

    14 days

  • Length of hospital stay

    Hospital stay

Study Arms (2)

1

ACTIVE COMPARATOR

Bronchoscopy

Procedure: Bronchoscopy

2

ACTIVE COMPARATOR

CPIS

Procedure: Clinical pulmonary infection score (CPIS)

Interventions

BronchoscopyPROCEDURE

Bronchoscopy procedure

1

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age \>= 18 years
  • Endotracheal intubation
  • Suspected VAP with:
  • New or progressive pulmonary infiltrates plus two of the following (In patients with pre-existing ALI or ARDS, physicians' suspicion of VAP with two of the listed criteria will be used.): Temperature \> 38 C or \< 36 C, WBC \> 12,000/mL or \< 4,000/mL, purulent endotracheal secretions.
  • Patient or legally authorized representative is able to sign Informed Consent

You may not qualify if:

  • Prison inmates
  • Immunocompromised patients
  • Participation in another trial conflicting with the design of the current trial
  • Previous history of VAP during the same hospitalization
  • Previous participation in the current study
  • Concomitant non-pulmonary infection diagnosed within 3 days preceding the suspected VAP
  • Patient's primary care provider does not want subject to be enrolled in the study
  • Contraindications for bronchoscopy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Afessa B, Hubmayr RD, Vetter EA, Keegan MT, Swanson KL, Baddour LM, Cockerill FR 3rd, Peters SG. Bronchoscopy in ventilator-associated pneumonia: agreement of calibrated loop and serial dilution. Am J Respir Crit Care Med. 2006 Jun 1;173(11):1229-32. doi: 10.1164/rccm.200512-1899OC. Epub 2006 Mar 9.

    PMID: 16528014BACKGROUND

MeSH Terms

Conditions

Pneumonia, Ventilator-Associated

Interventions

Bronchoscopy

Condition Hierarchy (Ancestors)

Healthcare-Associated PneumoniaCross InfectionInfectionsPneumoniaRespiratory Tract InfectionsLung DiseasesRespiratory Tract DiseasesIatrogenic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Diagnostic Techniques, Respiratory SystemDiagnostic Techniques and ProceduresDiagnosisEndoscopyDiagnostic Techniques, SurgicalMinimally Invasive Surgical ProceduresSurgical Procedures, OperativePulmonary Surgical ProceduresThoracic Surgical Procedures

Study Officials

  • Bekele Afessa, MD

    Mayo Clinic

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

December 22, 2007

First Posted

January 8, 2008

Study Start

January 1, 2007

Primary Completion

May 1, 2009

Study Completion

May 1, 2009

Last Updated

September 26, 2023

Record last verified: 2023-09